Factor XIa inhibition as a therapeutic strategy for atherothrombosis

Area of Science:

• Hematology
• Pharmacology
• Clinical Trials

Background:

• Current anticoagulants, including direct oral anticoagulants, carry bleeding risks, particularly gastrointestinal bleeding.
• Congenital factor XI (FXI) deficiency is associated with reduced risk of venous thromboembolism (VTE) and ischemic stroke (IS) without increased spontaneous bleeding.
• These epidemiological findings suggest FXI as a potential target for safer anticoagulation.

Purpose of the Study:

• To review the rationale for targeting FXI as a new anticoagulant strategy.
• To explain the potential for lower bleeding risk with FXI inhibitors compared to existing anticoagulants.
• To summarize ongoing and completed clinical trials evaluating FXI inhibitors.

Main Methods:

• Review of epidemiological data on FXI deficiency and thromboembolic/bleeding events.
• Analysis of the pharmacological basis for FXI inhibition in anticoagulation.
• Summary of clinical trial designs and outcomes for FXI inhibitors.

Main Results:

• Patients with FXI deficiency show a lower incidence of VTE and IS.
• Severe FXI deficiency does not correlate with an increased risk of spontaneous bleeding.
• Multiple FXI inhibitors are in development, with several in Phase III trials.

Conclusions:

• Targeting FXI represents a promising new therapeutic strategy for anticoagulation.
• FXI inhibitors may offer an improved safety profile with reduced bleeding complications.
• Further clinical trials are crucial to confirm the efficacy and safety of FXI inhibitors.